Skip to main content

Table 2 Basic information for studied polymorphisms

From: Characterization and risk association of polymorphisms in Aurora kinases A, B and C with genetic susceptibility to gastric cancer development

dbSNP Variant location Gene Base change NCBI assembly location (Build GRCh38)a TaqMan SNP assay ID Tag SNP (CEU population; HapMap)b Minor allele frequency (MAF)c
GC Patients Control group ALL EUR CEU
rs2273535 Missense AURKA A/T Chr.20:56386485 C_25623289_10 Yes 0.168 0.238 0.310 0.216 0.177
rs1047972 Missense AURKA C/T Chr.20:56386407 AHX1IRW No 0.088 0.146 0.150 0.182 0.157
rs911160 Intron AURKA G/C Chr.20:56382507 C_8947670_10 Yes 0.206 0.276 0.447 0.246 0.202
rs8173 3′ UTR AURKA G/C Chr.20:56369735 C_8947675_10 No 0.417 0.305 0.486 0.282 0.232
rs2241909 Synonymous AURKB A/G Chr.17:8205021 C_22272900_10 No 0.247 0.332 0.379 0.340 0.303
rs2289590 Intron AURKB C/A Chr.17:8207446 C_15770418_10 Yes 0.240 0.415 0.453 0.415 0.389
rs758099 Intron AURKC C/T Chr.19:57231966 C_2581008_1_ No 0.284 0.302 0.375 0.255 0.253
rs11084490 5′ UTR AURKC C/G Chr.19:57231104 C_27847620_10 Yes 0.139 0.223 0.132 0.165 0.177
rs42873 Intron PLK1 G/C Chr.16:23683411 C_2392140_10 Yes 0.230 0.208 0.234 0.215 0.192
  1. ALL All phase 3 individuals, EUR, European population, CEU, Utah residents with Northern and Western European ancestry, GC, Gastric cancer, UTR Untranslated region
  2. a https://www.lifetechnologies.com
  3. b https://snpinfo.niehs.nih.gov/snpinfo/snptag.html
  4. cMAFs extracted from 1000 Genomes Project Phase 3